SOURCE: Crucell N.V.

June 01, 2007 11:29 ET

Crucell announces resignations of Supervisory Board members, Dr. Jürg Witmer and Dr. Claude Thomann

LEIDEN, NETHERLANDS--(Marketwire - June 1, 2007) - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that the resignation of two Supervisory Board members, Dr. Jürg Witmer and Dr. Claude Thomann had been approved at the company's Annual General Meeting of Shareholders. Dr. Thomann and Dr. Witmer joined the Supervisory Board in February 2006 upon settlement of Crucell's exchange offer for Berna Biotech AG, where they each served as members of the Board of Directors prior to the acquisition. The departing Supervisory Board members will not be replaced.

Current Supervisory Board members are: Chairman Mr. Jan Pieter Oosterveld, Mr. Arnold Hoevenaars, Mr. Seán Lance, Mr. Phillip M. Satow, Mr. Dominik S. Koechlin and Mr. Claes Wilhelmsson. Serving terms for Mr. Lance and Mr. Wilhelmsson were extended today during the Annual General Meeting of Shareholders.

About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit

Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Crucell N.V. For Crucell in the US: Leonard Kruimer Redington, Inc. Chief Financial Officer Thomas Redington Tel. +31-(0)71- 519 9100 Tel. +1 212-926-1733

Barbara Mulder Director Corporate Communications Tel: 31-(0) 71 519 7346

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information